Review of real-world studies on capmatinib use in MET-mutated lung cancer
Lung cancer occupies a leading position in the structure of mortality from malignant neoplasms, so in 2022, mortality from lung cancer was 31.66 per 100,000 population, in 2022, 44,981 patients were registered with a diagnosis of lung cancer for the first time in their life, the one-year mortality r...
Saved in:
| Main Authors: | A. A. Kurylev, A. S. Kolbin, I. R. Svechkareva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Publishing House OKI
2025-04-01
|
| Series: | Реальная клиническая практика: данные и доказательства |
| Subjects: | |
| Online Access: | https://www.myrwd.ru/jour/article/view/87 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
by: R. Ben Dhiab, et al.
Published: (2025-06-01) -
Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions
by: Kinsley Wang, et al.
Published: (2024-10-01) -
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01) -
Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Lin Y, et al.
Published: (2025-06-01) -
Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review
by: Wenjing Yang, et al.
Published: (2025-02-01)